On Wednesday, Shares of Halliburton Company (NYSE:HAL), lost -2.24% to $40.94, as U.S. inventory data shows that there was an unpredictable enhance in crude supplies in the week that ended July 3, The Wall Street Journal reports.
US oil prices have dropped for the fifth straight trading session as domestic crude stockpiles rose again, but London prices inched higher.
US benchmark West Texas Intermediate for August delivery fell US68c, or 1.5 per cent, to $US51.65 a barrel, a three-month low.
Brent North Sea crude for August climbed US20c to settle at $US57.05 a barrel in London trade.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation. The Completion and Production segment provides production enhancement services, counting stimulation services and sand control services; and cementing services that comprise bonding the well and well casing, and casing equipment.
Shares of Eli Lilly and Company (NYSE:LLY), declined -1.67% to $87.25, during its last trading session.
On June 29, Eli Lilly and Company, and Immunocore Limited declared that they have reached an immunotherapy-based clinical trial partnershipto explore the utility of Immunocore’s lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. The aim of the partnership is to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas.
Under the terms of the agreement, Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted combining IMCgp100 with merestinib in metastatic uveal melanoma. Lilly will act as trial sponsor. These studies are anticipated to start in 2016. No financial terms were revealed.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
Finally, Kosmos Energy Ltd. (NYSE:KOS), ended its last trade with -4.16% loss, and closed at $7.84.
Kosmos Energy, declared the following plan for its second quarter 2015 results:
- Earnings Release: Monday, August 3, 2015, pre-market via Business Wire and the Company’s website at www.kosmosenergy.com.
- Conference Call: Monday, August 3, 2015, at 11:00 a.m. EDT. The call will be accessible via telephone and webcast.
Kosmos Energy Ltd. explores for and produces oil and gas in Africa, Europe, and South America. Its asset portfolio comprises production and other development projects in offshore Ghana, in addition to exploration licenses with hydrocarbon potential in offshore Ireland, Mauritania, Morocco, Senegal, and Suriname. The company was founded in 2003 and is based in Hamilton, Bermuda.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
